Japan Genomics Market Overview, 2030

Programs such the Japan Initiative for Global Research Network on Infectious Diseases (J-GRID) and the Initiative on Rare and Undiagnosed Diseases (IRUD) have helped Japan's genomics industry advance significantly. Japan has become a pioneer in genomic research at the population level thanks to these national initiatives, which place a strong emphasis on using genomics to improve healthcare outcomes for its citizens. One of the main goals has been to incorporate genomics into rare disease identification procedures in order to meet the medical requirements of those who have previously had their condition undiagnosed or misdiagnosed.

The Japan Agency for Medical Research and Development (AMED)-funded IRUD program has made it possible for hospitals, research institutions, and genome sequencing facilities to collaborate more effectively in order to enhance early identification and treatment of rare diseases. In Japan's sequencing initiatives, key roles have been played by universities such as Kyoto University and The University of Tokyo, as well as by major pharmaceutical firms such Takeda and Astellas Pharma. The quality and throughput of genomic studies have been greatly improved by these academic-industry collaborations, particularly in the fields of pharmacogenomics and personalized medicine.

Japan has also made significant investments in technological advancements, such as the introduction of third-generation sequencing platforms like long-read sequencing technologies, which are essential for deciphering complicated genomic regions, particularly in uncommon and inherited illnesses. Japan, however, faces a unique issue: its aging population is aging quickly.

This demographic change puts strain on the nation's genomic infrastructure, such as the availability of trained experts, data storage capabilities, and the integration of genomic data into regular clinical treatment, even if it increases the need for genomics-driven healthcare treatments. It is critical to address these infrastructural deficiencies in order to maintain growth and maximize the potential of genomics in enhancing public health outcomes.

According to the research report, "Japan Genomic Market Overview, 2030," the Japan Genomic market is anticipated to grow at more than 16.46% CAGR from 2025 to 2030. Several confluent elements are fueling this growth, the most important of which is Japan's aging population, which is increasing demand for precision treatments that are customized to the unique genetic and molecular profiles of older patients. Genomic medicine, which is poised to be a crucial component of Japan's future healthcare plan, holds the promise of better treatments for age-related chronic diseases like cancer, cardiovascular conditions, and neurodegenerative illnesses.

The introduction of national cancer genome screening programs, notably via the Center for Cancer Genomics and Advanced Therapeutics (C-CAT) initiative, is one of the most notable advancements in Japan's genomics industry. In line with the national aim of offering tailored cancer treatments based on individual genomic profiles, this platform gathers and analyzes genomic data from cancer patients all throughout the nation. These initiatives are a crucial step towards integrating genomics into the Japanese healthcare system.

Research institutes like RIKEN, a pioneer in big genomic research, and companies like Takara Bio, which creates and sells vital genomic products like sequencing kits and gene therapy platforms, are among the key players driving innovation and commercialization in Japan's genomics industry. Furthermore, Japan's biotechnology environment has promoted cooperation between universities, pharmaceutical firms, and diagnostic service providers in order to speed up the use of genomics. The usage of genomics in anti-aging and longevity studies is becoming more popular in Japan. Genomic techniques are increasingly being used in Japan to investigate the genetic basis of healthy aging and possible treatments for increasing the quality of life as the nation confronts the problems brought about by an aging population.

The genomics market by product is divided into Products and Services. The majority of the products in this sector are reagents and consumables, like molecular probes, PCR master mixes, sequencing reagents, and DNA extraction kits. These are necessary for carrying out genomic processes in hospitals and labs. Important product categories include bioinformatics software for genomic data analysis and sequencing platforms, such as next-generation sequencing (NGS) instruments. Gene editing technologies, especially those based on CRISPR, are becoming increasingly popular for sophisticated research applications. Major companies in Japan that sell these goods include Takara Bio Inc., Sysmex Corporation, RIKEN Genesis, and MBL.

For instance, Takara Bio offers reagents, instruments, and services related to PCR, gene therapy, and NGS. The demand for these products is fueled by technologies such as NGS, PCR, and microarrays, which make it possible to analyze genomics more quickly and accurately, particularly in diagnostics and personalized medicine. The main users of genomic products in Japan are research institutions, biotechnology firms, diagnostic labs, hospitals, and pharmaceutical companies. In terms of applications, genomic products are widely used in the developing field of pharmacogenomics, rare disease diagnostics, and oncology research.

In Japan's genomics market, the services category includes sequencing services, bioinformatics analysis, genetic counseling, and genomic data storage solutions. Leading service providers include RIKEN Genesis, Macrogen Japan, and international players like Illumina Japan, which offers NGS services catered to the requirements of clinical and research facilities. The use of genomic services spans a wide range of fields, including oncology, infectious diseases, pharmacogenomics, and agricultural genomics. Furthermore, these products and services are becoming more and more popular in precision medicine initiatives, regenerative medicine, and anti-aging research.

The use of cutting-edge technologies that have revolutionized genomic research and clinical diagnosis is what drives Japan's genomics industry. The top technology is currently Next-Generation Sequencing (NGS), which provides high-throughput sequencing of whole genomes, exomes, and targets. In Japan, NGS is essential for pharmacogenomics, rare disease identification, and cancer diagnosis.

National programs, such as cancer genome screening programs, under Japan's Center for Cancer Genomics and Advanced Therapeutics (C-CAT) further support the use of NGS. In genomic workflows, the polymerase chain reaction (PCR) is still a fundamental technique. In Japan, companies like Takara Bio Inc. and Sysmex are major suppliers of PCR systems and reagents.

They support research and clinical diagnostics, including applications in infectious disease testing, and are widely utilized for gene amplification, mutation detection, and pathogen identification. Despite a decline in market share with the advent of NGS, microarrays are still valuable, especially for SNP genotyping and gene expression profiling. In academic research facilities and certain clinical uses, like pharmacogenetic investigations, microarrays are still widely used. The original DNA sequencing technique, Sanger sequencing, is still utilized in Japan for validation of NGS findings and for small-scale sequencing. Its accuracy is extremely useful for validating genetic variations found in diagnostic workflows.

Although it is supportive, flow cytometry is essential to cell-based genomic research, particularly for applications in cancer biology and immunogenomics. In translational research projects that link genomics with immunotherapy approaches, flow cytometry is extensively employed. In Japan's genomic R&D environment, especially for regenerative treatments and precision medicine, other technologies such CRISPR-Cas9 gene editing and single-cell sequencing are becoming game-changing instruments.

Reflecting Japan's dedication to using genomic science for both healthcare and scientific advancement, the nation's genomics industry covers a wide range of applications. The top application category is Diagnostics, with a focus on oncology, cardiology, rare diseases, and infectious diseases. The integration of genomics into cancer diagnostics has been prioritized by Japan's National Cancer Genome Screening Program, allowing for individualized treatment plans. Genomic testing has become a crucial tool for diagnosing and treating rare and hereditary genetic illnesses due to Japan's strong emphasis on identifying them.

Genomic diagnostics are also utilized in infectious disease surveillance, which has become more of an emphasis during and after the COVID-19 outbreak. Genomics is essential to identifying new biomarkers and therapeutic targets in drug discovery and development. Pharmaceutical behemoths such as Takeda Pharmaceutical and Astellas Pharma use genomics in their research and development strategies to expedite the creation of targeted therapies, notably for cancer, neurological disorders, and metabolic diseases. Due to an aging society that needs individualized therapy methods, precision medicine is becoming increasingly popular in Japan.

Initiatives like the Center for Cancer Genomics and Advanced Therapeutics (C-CAT) promote the incorporation of genomic data into customized treatment regimens, demonstrating Japan's dedication to accurate healthcare. For human health, genomics has important applications in Japan in the fields of agriculture and animal genomics. Genomic approaches are used by research organizations to enhance livestock breeding initiatives, crop yields, and disease resistance.

Japan's agricultural modernization, which has prioritized food security and sustainability, has been aided by advancements in plant genomics. Genomics is also used in other fields like forensic genomics, population genetics, and nutrigenomics, where genomic profiles are used to make dietary recommendations for healthy aging. Furthermore, Japan's demographic changes are driving the development of genomics-based anti-aging research.

Considered in this report

• Historic Year: 2019
• Base year: 2024
• Estimated year: 2025
• Forecast year: 2030

Aspects covered in this report

• Genomic Market with its value and forecast along with its segments
• Various drivers and challenges
• On-going trends and developments
• Top profiled companies
• Strategic recommendation

By Product & Services

• Products
• Services

By Technology

• Next-Generation Sequencing (NGS)
• PCR
• Microarrays
• Sanger Sequencing
• Flow Cytometry
• Others

By Application

• Diagnostics (Oncology, Cardiology, Rare Diseases, Infectious Diseases, Others)
• Drug Discovery and Development
• Precision Medicine
• Agriculture & Animal Genomics
• Other Applications

The approach of the report:

This report consists of a combined approach of primary as well as secondary research. Initially, secondary research was used to get an understanding of the market and listing out the companies that are present in the market. The secondary research consists of third-party sources such as press releases, annual report of companies, analyzing the government generated reports and databases.

After gathering the data from secondary sources primary research was conducted by making telephonic interviews with the leading players about how the market is functioning and then conducted trade calls with dealers and distributors of the market. Post this we have started doing primary calls to consumers by equally segmenting consumers in regional aspects, tier aspects, age group, and gender. Once we have primary data with us we have started verifying the details obtained from secondary sources.

Intended audience

This report can be useful to industry consultants, manufacturers, suppliers, associations & organizations related to this industry, government bodies and other stakeholders to align their market-centric strategies. In addition to marketing & presentations, it will also increase competitive knowledge about the industry.

Considered in this report

• Historic Year: 2019
• Base year: 2024
• Estimated year: 2025
• Forecast year: 2030

Aspects covered in this report

• Genomic Market with its value and forecast along with its segments
• Various drivers and challenges
• On-going trends and developments
• Top profiled companies
• Strategic recommendation

By Product & Services

• Products
• Services

By Technology

• Next-Generation Sequencing (NGS)
• PCR
• Microarrays
• Sanger Sequencing
• Flow Cytometry
• Others

By Application

• Diagnostics (Oncology, Cardiology, Rare Diseases, Infectious Diseases, Others)
• Drug Discovery and Development
• Precision Medicine
• Agriculture & Animal Genomics
• Other Applications

The approach of the report:

This report consists of a combined approach of primary as well as secondary research. Initially, secondary research was used to get an understanding of the market and listing out the companies that are present in the market. The secondary research consists of third-party sources such as press releases, annual report of companies, analyzing the government generated reports and databases.

After gathering the data from secondary sources primary research was conducted by making telephonic interviews with the leading players about how the market is functioning and then conducted trade calls with dealers and distributors of the market. Post this we have started doing primary calls to consumers by equally segmenting consumers in regional aspects, tier aspects, age group, and gender. Once we have primary data with us we have started verifying the details obtained from secondary sources.

Intended audience

This report can be useful to industry consultants, manufacturers, suppliers, associations & organizations related to this industry, government bodies and other stakeholders to align their market-centric strategies. In addition to marketing & presentations, it will also increase competitive knowledge about the industry.